



## HYALURONIDASE (HYALASE<sup>®</sup>) – DRUG SAFETY INFORMATION

Form: Dry powder for reconstitution, 1500 iu/vial

### General:

- If there is evidence of damage to the packaging in transit please contact us prior to administration.
- Keep out of the reach and sight of children.
- Store at ambient temperature below 25°C until ready to use.
- **For Single Patient Use Only:** Use immediately after reconstitution and discard any unused solution.
- Hyaluronidase is not an anti-neoplastic agent and therefore unused product or disposables used for administration can be disposed of in containers used for routine clinical sharps waste.

### Handling and administration:

This medication is provided as a powder for reconstitution with 0.9% NaCl. Dissolve by vigorous shaking. Once reconstituted the solution is for **local infiltration only** and should not be administered systemically. An insulin syringe may be effective in administering small volumes of the medication.

The drug should be not be stored once reconstituted.

Sedation is required for administration as this may be uncomfortable.

There are few guidelines but in the interests of safety, pregnant women should not be involved in the administration of hyaluronidase. There are no studies currently however that indicate that there is a hazard during pregnancy or breast feeding.

### Prevention of contamination:

- Routes of exposure to pharmaceutical agents include ingestion, inhalation, and absorption through the skin and mucous membranes. Accidental needle stick injury should be avoided.
- There are no specific guidelines on wearing PPE (gown, gloves, mask, eye protection) for reconstitution and administration of this medication however normal precautions to prevent exposure to pharmaceutical agents should be observed.

### Disposal:

Used vials and contaminated disposables may be discarded into a sharps bin and treated as clinical waste.

**Warnings and contraindications:**

In humans rare allergic reactions have been reported together with local irritation, oedema and bruising. Side effects in veterinary patients have not been reported nor documented.

**Further information:**

Further information is available on request by contacting us at [info@chemopet.co.uk](mailto:info@chemopet.co.uk) or by telephone: 01928 250052.